Vensana Capital β Full Portfolio
32 tracked investments Β· listed companies and verified rows first
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)Nadim Yared(Executive Officer, Director)Dean Bruhn-Ding(Executive Officer)John Brintnall(Executive Officer)Liz Galle(Executive Officer)
BoardGeoff Pardo(Director)
Board seatKirk NielsenΒ· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalHatteras Venture Partners
BiotechGermantown, US
Mukul Jain(Executive Officer)Francine R. Kaufman(Executive Officer, Director)Rick Sullivan(Executive Officer)Kenneth L Horton(Executive Officer)Timothy T. Goodnow(Executive Officer, Director)Mirasol Panlilio(Executive Officer)
Board seatPeter Justin KleinΒ· per SEC Form D Β· $30M raise Β· filed Sep 2020
Co-investorsNew Enterprise Associates (NEA)
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Malik Kahook(Executive Officer, Director)Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)Patrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapital
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.
BiotechHealthtechMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Murali Padala(Co-founder)Eric Sarin(Co-founder)
Co-investorsBroadview VenturesEpidarex CapitalGRA Venture
Vensana Innovation is a venture-backed startup studio ("innovation engine") that launches and builds medical technology companies, providing capital along with technical, clinical, commercial, and business development support at all stages from ideation to commercialization.
Deep TechHealthtechMedical Devices
Ben(Co-founder)Thomas Tu(CEO & Venture Partner)inBrian(Founding Member)Phil Marchand
Vesper Medical develops a modular venous stent portfolio designed to address the anatomical challenges of the iliac and femoral veins for treating deep venous disease.
HealthtechMedical DevicesWayne, US
Bruce J. Shook(President and CEO)Monica Klos(Executive Officer)Neil Hattangadi(Director)Peter Schneider(Director)Mark Garcia(Director)Dennis W. Wahr(Director)
Co-investorsNew Enterprise Associates (NEA)Gilde HealthcareLightstone Ventures415 Capital
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)Jacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)
Board seatKirk NielsenMaria BerkmanΒ· per SEC Form D
Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLC+1 more
Artelon develops synthetic ligament and tendon reconstruction products based on its Dynamic Matrix technology for orthopedic soft tissue repair.
BiotechHealthtechMedical DevicesNew MaterialsMarietta, US
Lars Peterson(Founder)Aaron Smith(Executive Officer, Director)Mark Cohen(Director)Jeff Byrne(Executive Officer)Carter Meyer(Director)Steve Becker(Director)
Board seatKirk NielsenΒ· per SEC Form D
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)Gregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)Axel Scherer(Director)
Board seatJustin KleinΒ· per SEC Form D
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Cleerly develops FDA-cleared, AI-driven analysis of noninvasive coronary CT (CCTA) imaging to characterize and quantify coronary artery disease.
AI & Machine LearningDigital HealthMedical DevicesDenver, US
James Min, MD(Founder)inJames K. Min(Executive Officer, Director)in
BoardLee Cooper(Director)Scott Barclay(Director)Louis Samson(Director)
Board seatPeter Justin KleinΒ· per SEC Form D Β· $106.3M raise Β· filed Dec 2024
Co-investorsBattery VenturesBreyer CapitalInsight PartnersLRVHealthNew Leaf Venture Partners
IVEAcare develops neuromodulation and bioelectronics therapies, implantable medical devices aimed at treating chronic conditions for large patient populations.
Deep TechHealthtechMedical DevicesRoseville, US
Todd Kerkow(Co-Founder, President and CEO)inMudit Jain(Co-Founder and Chairman of the Board)Lynn(Co-Founder and Board Member)inCorey Dishmon(Director)Robert Greenberg(Director)
Board seatAmrinder SinghKirk NielsenΒ· per SEC Form D
Co-investorsTreo Ventures, LlcHatteras Venture Partners
Overnight automated insulin delivery
Wilmington, US
John Sjolund(Chief Executive Officer of the Issuer)Jon Brilliant(Chief Financial Officer of the Issuer)
BoardPeter N. Townsend(Director)
Board seatJustin KleinAmrinder SinghΒ· per SEC Form D
Co-investorsSerpentine Ventures
Monteris develops minimally invasive laser ablation technology (LITT) used to treat brain conditions including oncology tumors and drug-resistant epilepsy.
BiotechHealthtechMedical DevicesPlymouth, US
JAMES ERICKSON(Executive Officer)MARTIN EMERSON(Executive Officer, Director)John Schellhorn(Executive Officer, Director, Promoter)Robert K Davidson(Executive Officer)Gregory Barrett(Director)Gary Bantle(Director)
Board seatKirk NielsenBill HoffmanΒ· per SEC Form D Β· $13.7M raise Β· filed Sep 2022
Co-investorsThe Vertical Group
Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters.
BiotechHardwareHealthtechMedical DevicesAliso Viejo, US
Brian J. Cox(Manager)Rhonda Robb(Executive Officer, Director)Robert Rosenbluth(Director)
BoardDonald Milder(Director)Jonathan Root(Director)inPaul Lubock(Director)
Board seatMike KramerKirk NielsenΒ· per SEC Form D
Co-investorsUS Venture PartnersGilde Healthcare
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
BiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)Luis A. Diaz, Jr.(Executive Officer, Director, Promoter)Lisa Kann(Executive Officer)Sam Angiuoli(Executive Officer)Felix Dawson(Director)Anthony Newton(Executive Officer)
Board seatJustin KleinΒ· per SEC Form D
Co-investors3B Future Health FundCatalio Capital Management, LPCo-Win VenturesNew Enterprise Associates (NEA)Windham Capital Partners
HealthtechBirmingham, US
Tom Livingston(Executive Officer, Director)Michael Jackson(Executive Officer)Robert E. Foster, M.D.(Executive Officer, Director)
BoardChase Wise(Director)
Board seatMike KramerKirk NielsenΒ· per SEC Form D Β· $21.7M raise Β· filed May 2025
Relievant offers the Intracept Procedure, a minimally invasive, FDA-cleared medical intervention designed to relieve chronic low back pain caused by vertebrogenic pain.
Medical DevicesRedwood City, US
Alex DiNello(Executive Officer, Director)
BoardRichard Mott(Director)Brent Ahrens(Director)inJason Lettman(Director)John Ryan(Director)
Board seatJustin KleinΒ· per SEC Form D
Co-investorsCanaan PartnersEmergent Medical Partners, LLPLightstone VenturesNew Enterprise Associates (NEA)
Tybrhealth develops the B3 GELβ’ System, a protective gel applied during tendon and ligament repair surgery to reduce post-operative scar formation and preserve tissue mobility.
BiotechHealthtechMedical DevicesHouston, US
Tim Keane(Founder)inAlex Smith(Founder)inJeffrey Tyber(Director)Stephen Ramon(Executive Officer)Timothy J. Keane, Jr.(Executive Officer, Director)
BoardToby Hamilton(Director)
Board seatGreg BankerΒ· per SEC Form D
Co-investorsAsymmetry VenturesY CombinatorMutual Capital PartnersVentureSouq
BiotechSan Carlos, US
Surag Mantri(Executive Officer, Director)
BoardMatthew Sprinkel(Director)Amir Abolfathi(Director)Varun Gupta(Director)
Board seatJustin KleinΒ· per SEC Form D
Co-investorsBoutique Venture PartnersLongitude CapitalNeotribe Ventures
Edina, US
BoardThomas Tu(Executive Officer)inWilliam Hoffman(Executive Officer)inSteven Schwen(Executive Officer)in
Board seatMaria BerkmanKirk NielsenΒ· per SEC Form D Β· $25M raise Β· filed Aug 2025
Apella provides an ambient AI platform that connects to the EHR to give hospital surgical teams real-time operating room intelligence, case duration forecasts, and automated documentation.
AI & Machine LearningDigital HealthHealthtech
Co-investorsK2 HealthVenturesLayout VenturesOPAMP CAPITALTwine Ventures
Cleerly is an AI-enabled software platform that analyzes coronary artery disease through advanced imaging analysis, providing clinically actionable insights to support heart attack prevention and personalized patient care.
AI & Machine LearningHealthtechMedical Devices
Co-investorsBreyer CapitalDigiTx Partners LLCLRVHealth
Evident Vascular develops an intravascular ultrasound (IVUS) platform that uses AI for image interpretation and workflow improvements, aimed at peripheral vascular applications.
AI & Machine LearningHealthtechMedical Devices
Danielo Piazza(Founder)Howard Rosen(Founder)
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersLightstone VenturesLongitude CapitalNew Enterprise Associates (NEA)
Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.
HardwareHealthtechMedical DevicesIrvine, US
William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)
BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)
Co-investorsGilde HealthcareUS Venture PartnersVersant Ventures
BiotechHealthtechWayne, US
Robert Giasolli(Executive Officer)Carol Burns(Executive Officer)Marc Penna(Executive Officer)Monica Klos(Executive Officer)Dennis Wahr(Director)P. Sherrill Neff(Director)
Co-investors415 CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersRunway Growth CapitalH.I.G. BioHealth PartnersNew Enterprise Associates (NEA)
Luna Diabetes builds an automated insulin delivery system for people with diabetes who use insulin pens (MDI) rather than traditional insulin pumps.
Digital HealthHealthtechMedical Devices
Co-investorsInterlock CapitalSerpentine VenturesWinklevoss Capital
Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases.
BiotechHealthtechMedical Devices
Co-investorsSanderling Ventures
St.
HealthtechSt. Louis, US
Scott Wrightstone(Executive Officer)Maureen Oehler(Executive Officer)Jason Pesterfield(Executive Officer, Director)Ryan Denney(Executive Officer)Mark Hunter(Executive Officer)Troy Holsing(Executive Officer)
Co-investorsRC CapitalRex Health Ventures
Co-investorsLightstone Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.